Lehigh Valley Health Network LVHN Scholarly Works

Research Scholars Poster Presentation

Outcomes of Implantable Cardioverter Defibrillator (ICD)/Pacing Lead Extraction Over 8 Years

Alexandra Reph Lehigh Valley Health Network, Alexandra.Reph@lvhn.org

Sophie Pickering *Lehigh Valley Health Network*, Sophie.Pickering@lvhn.org

Caitlin Hoeing

Lehigh Valley Health Network, Caitlin.Hoeing@lvhn.org

Samrah Ansari Lehigh Valley Health Network, Samrah. Ansari@lvhn.org

James K. Wu MD

Lehigh Valley Health Network, james.wu@lvhn.org

Follow this and additional works at: https://scholarlyworks.lvhn.org/research-scholars-posters

Published In/Presented At

Reph, A. Pickering, S. Hoeing, C. Ansari, S. Wu, J. K. (2019, August). *Outcomes of Implantable Cardioverter Defibrillator (ICD)/Pacing Lead Extraction Over 8 Years*. Poster Presented at: LVHN Research Scholar Program Poster Session, Lehigh Valley Health Network, Allentown, PA.

This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an authorized administrator. For more information, please contact LibraryServices@lvhn.org.

Outcomes of Implantable Cardioverter Defibrillator (ICD)/Pacing Lead Extraction **Over 8 Years**

Alexandra Reph, Sophie Pickering, Caitlin Hoeing, Samrah Ansari, James K. Wu, MD

Division of Cardiothoracic Surgery

Lehigh Valley Health Network, Allentown, Pennsylvania

Background


- · Cardiac Implantable Electronic Devices (CIED) are used to regulate a patient's heartbeat when arrhythmia is present
- Indications for lead extraction include lead and pocket infection, lead fracture, skin erosion, recalled lead, lead migration or dislodgement
- Due to binding tissue that can form around the leads if implanted for multiple years, extraction can be challenging. An understanding of complication risk factors is beneficial for optimal CIED management and lead extraction decision making

Objectives

- Gain a better understanding of LVHN Lead-Extraction Patient Population.
- Determine any correlation between identified risk factors and survivability. 2.
- Analyze Complication and Mortality Rates (Perioperative, 30 Day, Yearly)
- Evaluate overall intraoperative and postoperative outcomes.


Methods

Retrospective study of 195 adult patients with the discharge condition of lead extraction treated at LVHN CC over an eight year period, from 2011 to 2018.



| Table 1: Population Demographics | | | | | |
|----------------------------------|---------------|---|-------------|--|--|
| Age (Mean, SD) | 67.19 (15.28) | Chronic Renal Disease 60 (39.5% | | | |
| > 75 | 73 (37.4%) | On Dialysis | 13 (6.7%) | | |
| Male | 133 (68.2%) | Peripheral Vascular Disease (PVD) | 28 (15.4%) | | |
| Female | 59 (30.3%) | Previous Cerebrovascular Accident (CVA) | 19 (12.8%) | | |
| ICD Device | 131 (68.2%) | Hypertension | 142 (72.8%) | | |
| Pacemaker Device | 64 (32.8%) | Previous Myocardial Infarction (MI) | 43 (25.1%) | | |
| Current Tobacco Use | 26 (13.3%) | Previous Open Heart Surgery (OHS) | 51 (26.2%) | | |
| Anticoagulents | 109 (55.9%) | Anemia | 49 (30.8%) | | |
| Ejection Fraction <50% | 106 (54.4%) | Chronic Obstructive Pulmonary Disease COPD) | 42 (22.1%) | | |
| Diabetes Mellitus | 77 (42.6%) | Coronary Artery Disease (CAD) | 104 (72.8%) | | |

Outcomes Figure 2: Procedural Figure 1: Indications for Extraction Lead Fracture/Dysfunction Lead Vegetation Recalled Lead Device ERI Lead Related Endocarditis Complete Lead Skin Erosion Removal (90.8%) End of Therapy/Device Upgrade ■ Partial Lead Lead Migration Removal (7.2%) Pain Due to Device Emergent Surgical Retained Lead Intervention (1.5%)





| Table 2: Hospital Stay | | Table 4: Risk Factors and Respective Complication Rates | | |
|--------------------------|------------|---|------------|----------------------|
| Median Length of Stay | 5 Days | Risk Factor | Patients | Subset Population |
| Average Postop | 6.05 Days | ICD Device Extraction | 15.3% (20) | 131 |
| to Discharge | | Extraction Due to | 18.0% (14) | 78 |
| Readmission | 13.4 % | Infection | | |
| Within 30 Days | | 3+ Leads Extracted | 20.0% (8) | 40 |
| Table 3: Mortality Rate | | *Leads >5 Years Old | 12.5% (6) | 48 |
| Perioperative | 3.1% (6) | Females | 15.3% (9) | 59 |
| 30 Day | 4.1% (8) | Not On | 15.1% (13) | 86 |
| | . , | Anticoagulents | | |
| 1 Year | 15.9% (31) | *High Risk Cohort | 16.7% (8) | 60 |

Hypotension (1)

*A High Risk cohort of 48 patients was established using the following criteria: 75+ years of age: >2 comorbidities.

Results







Conclusions

- · Patients in increased risk subsets (Infection as Extraction Indication; 3+ Leads Extracted) have a significantly lower survivability rate than those in the general population
- · LVHN Lead Extraction Patients have a higher age and high risk demographic, however mortality and complication rates are kept low
 - Age: >75 Years 37.4%
 - · High Risk: >2 Comorbidities 69.7%
 - · Complication Rate: 15.4%
 - · Perioperative Mortality Rate: 3.1%
- · Future Steps:
 - Further Exploration Within Significant Risk Factor Subsets
 - · Infection Prevention and Awareness: Antibiotic Envelope/Emerging

References



